Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project).

[1]  C. Pashos,et al.  The health economics of bladder cancer , 2012, PharmacoEconomics.

[2]  Ewout W Steyerberg,et al.  Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). , 2009, European urology.

[3]  M. Zeegers,et al.  The effect of smoking on the male excess of bladder cancer: A meta‐analysis and geographical analyses , 2009, International journal of cancer.

[4]  D. Parkin,et al.  The global burden of urinary bladder cancer , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[5]  S. Janković,et al.  Risk Factors for Bladder Cancer , 2007, Tumori.

[6]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[7]  E. Zwarthoff,et al.  A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine , 2005, Clinical Cancer Research.

[8]  T. Kwast,et al.  Urine markers for bladder cancer surveillance: a systematic review. , 2005 .

[9]  Bas van Rhijn,et al.  Molecular Diagnosis and Prognosis of Bladder Cancer : towards the implementation of molecular markers in clinical practice , 2005 .

[10]  E. Messing,et al.  Detection of bladder cancer using a point-of-care proteomic assay. , 2005, JAMA.

[11]  L. Ronningen.  Campbell's Urology, 8th ed , 2005 .

[12]  Gangning Liang,et al.  Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients , 2004, Clinical Cancer Research.

[13]  R. Uzzo,et al.  Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel , 2004, Clinical Cancer Research.

[14]  T. Hampton.  New anti-BSE rules imposed. , 2004, JAMA.

[15]  K. Rieger-Christ,et al.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection , 2003, Cancer.

[16]  M. Soloway,et al.  Current bladder cancer tests: unnecessary or beneficial? , 2003, Critical reviews in oncology/hematology.

[17]  Marije Deutekom,et al.  Tumor markers in the diagnosis of primary bladder cancer. A systematic review. , 2003, The Journal of urology.

[18]  T. H. van der Kwast,et al.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Chan,et al.  Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients , 2003, International journal of cancer.

[20]  T. H. van der Kwast,et al.  Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Goldbohm,et al.  Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands , 2001, Occupational and environmental medicine.

[22]  M. Droller.  BLADDER, PENIS AND URETHRAL CANCER, AND BASIC PRINCIPLES OF ONCOLOGY , 2001 .

[23]  D. Bostwick,et al.  Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma , 2000, Cancer.

[24]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[25]  David Sidransky,et al.  Detection of bladder cancer recurrence by microsatellite analysis of urine , 1997, Nature Medicine.

[26]  E. Messing,et al.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. , 1995, Urology.

[27]  A. Dowell,et al.  A community study of bladder cancer screening by the detection of occult urinary bleeding. , 1992, The Journal of urology.

[28]  N. Heney,et al.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course. , 1992, The Urologic clinics of North America.

[29]  E. Messing,et al.  Home screening for hematuria: results of a multiclinic study. , 1992, The Journal of urology.

[30]  W. Catalona,et al.  Urothelial Tumors of the Urinary Tract , 1992 .

[31]  A. Dowell,et al.  Dipstick haematuria and bladder cancer in men over 60: results of a community study. , 1989, BMJ.

[32]  W. Catalona,et al.  Management of Superficial Bladder Cancer , 1987 .